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Background. Impulsive behaviour has become increasingly recognised as a neuropsychiatric complication of Parkinson’s disease
(PD). 'ought to be a product of compromised cognitive control, the spectrum of impulsive behaviours in PD ranges from
cognitive disinhibition to impulse control disorders (ICDs). Objective. At present, there are no indicators for trait impulsivity in
PD.'e objective of the current study was to identify demographic and clinical predictors of susceptibility to trait impulsivity in a
cohort of PD patients. Methods. 'e current study assessed impulsivity using the Barratt Impulsiveness Scale 11 (BIS-11) in
a cohort of 87 PD patients. General linear models (GLMs) were used to identify clinical and demographic variables predictive of
heightened BIS-11 second-order attentional and nonplanning subscale scores. Results. Male gender, no history of smoking,
postsecondary education, and heightened disease severity were predictive of increased BIS-11 attentional scores (p< 0.05).
Similarly, male gender, after secondary education, and disease severity were predictive of increased BIS-11 nonplanning scores
(p< 0.05). Contrary to previous reports, dopaminergic medication use was not a significant determinant of either BIS-11 subscale
scores. Conclusions. Several demographic and clinical variables including male gender, no history of past smoking, after secondary
education, and elevated disease severity are associated with impulsivity in PD.
1. Introduction
In recent times, a variety of impulsive behaviours, often ranging
in severity, have been reported as psychiatric complications
associated with Parkinson’s disease (PD) [1]. As a construct,
impulsivity is broadly defined as the tendency to act prematurely
or without foresight, with little regard for the often-negative
consequences associated with these actions [2].
Previous studies suggest that PDpatients display heightened
impulsivity, particularly when taking dopaminergic medication
[1, 3]. In addition to this, PDmay impair response inhibition, an
integral element of impulsivity, with PD patients performing
worse on a range of measures of inhibition, including the Stop-
Signal Task [4, 5], Go/No-Go [6], and antisaccade [7].
Impulsivity is thought to underlie several psychiatric dis-
orders described in PD, particularly impulse control disorders
(ICDs) including pathological gambling, compulsive shopping
and eating, and hypersexual behaviours [1, 8, 9]. 'ese behav-
iours represent extreme manifestations of impulsivity thought to
be provoked by dopamine agonist [10] therapy and identified
in only 13% of PD patients [11]. Despite the strong association
between impulsivity and ICDs, PD patients may display im-
pulsivity even in the absence of an ICD [8, 12]. Additionally,
impulsivity represents a significant risk factor for the onset of
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an ICD, which further suggests that impulsivity in PD can be
represented on a spectrum; beginning with mild cognitive and
motor disinhibition and eventually manifesting as clinically
identifiable ICDs [9].
Previous studies have identified several variables associ-
ated with ICDs including male gender [11], cigarette smoking
history [11, 13, 14], dopamine agonist use [11, 13], younger
age of disease onset [14, 15], a history of drug or alcohol abuse
[9, 15], and a novelty-seeking personality [9, 15]. However,
there are no current demographic or clinical indicators of
future impulsivity in PD. Given the strong association be-
tween impulsivity and ICDs in addition with the absence of
treatment options for impulsive behaviour, the identification
of risk factors for trait impulsivity serves as a valuable clinical
tool in optimising the prevention of impulsivity and, in turn,
the future onset of ICDs.
As such, the present study characterised a heterogeneous
cohort of Western Australian PD patients with the objective of
identifying demographic and clinical predictors for the devel-
opment of trait impulsivity. Trait impulsivity was assessed using
the Barratt Impulsiveness Scale 11 (BIS-11), which has been used
extensively in PD clinical settings. 'e BIS-11 is a reliable
measure of trait impulsivity, addressing the complexity of im-
pulsivity as a construct with a three-component conceptualiza-
tion comprising attentional impulsivity (reduced ability to focus
on the task at hand and racing thoughts), motor impulsivity (the
tendency to act without thinking), and nonplanning impulsivity
(lack of future- or fore-thought) [16]. Previous studies have
shown adequate internal consistency of BIS-11 second-order
attentional and nonplanning subscales with Cronbach’s α of 0.74
and 0.72, respectively [17]. However, internal consistency of the
BIS-11 second-order Motor subscale is below adequate with
a Cronbach’s α of 0.59 [17]. Further, the aim of the current study
was to assess cognitive domains of impulsivity in PD, rather than
motor domains. 'erefore, in the current study assessed only
subjects BIS-11 attentional and nonplanning scores.
2. Methods
2.1. Subjects. Eighty-seven home-based PD patients (54 males)
were sequentially recruited from the Movement Disorders Clinic
at the Perron Institute for Neurological and Translational Science
(Perth, Australia) between 2008 and 2015. All patients were
examined by a movement disorder neurologist prior to inclusion
in the study for verification of the diagnosis in accordance with
the UK Brain Bank criteria for IPD. All patients were taking
levodopa, and 45 patients were on a dopamine agonist (pra-
mipexole, rotigotine, and apomorphine). Formedication dosages,
LEDDwas calculated from patient medication dosages as per the
following: LEDD� (regular levodopa dosage)+0.75 (slow-release
levodopa)+ 10 (bromocriptine) + 10 (pergolide) + amantadine.
Fourteen patients had undergone deep brain stimulation
(DBS) therapy. Demographic variables including a history of
smoking and patients’ level of education were also collected.
2.2. Clinical Assessments and Impulsivity Screening. All clinical
assessments were evaluated in the “ON” state. Motor symp-
toms were evaluated using the MDS-Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) Part III and Hoehn and
Yahr Scale. In addition, each participant was evaluated by
a clinical psychologist and completed a battery of neuro-
psychological assessments, as previously described [18]. 'e
Mini-Mental State Examination (MMSE) was used to determine
patients’ cognitive status, with an MMSE score of less than 26
indicating “cognitive impairment” and greater than 26 in-
dicating “normal” cognition. 'e “Barratt Impulsivity Scale 11”
(BIS-11) was employed as a validated self-report questionnaire
for screening impulsivity. 'e BIS-11 consists of 30 questions
scored on a four-point scale, with each item corresponding to
one of the three BIS-11 second-order subscales. 'e current
study aimed to investigate cognitive domains of trait impulsivity
rather thanmotor impulsivity and therefore only BIS-11 second-
order attentional and nonplanning subscale scores are presented.
Questions corresponding to these subscales are summarised
in Table 1. Overall BIS-11 scores were calculated as the sum
of these 30 scores (to yield a score out of 120), with higher
scores indicating greater impulsivity. 'e sum of second-order
BIS-11 attentional and nonplanning items was used to calculate
patients’ BIS-11 second-order subscale scores. BIS-11 second-
order attentional and nonplanning scores were scored out of 32
and 44, respectively. During the screening process, patients
displaying any signs of an impulse control disorder were in-
vited to seek further consultation with the clinical psychologist.
2.3. Statistical Methods. Data were analysed using IBM-SPSS
(v. 24, IBM Corporation). A significant nominal p value of
<0.05 was employed. Univariate regression analysis of con-
tinuous demographic and clinical variables (MDS-UPDRS III,
disease duration, and LEDD) and categorical demographic
variables and clinical variables (gender, smoking history, level
of education, i.e., secondary school or tertiary education, and
cognitive status) was performed in order to determine whether
these variables were significantly associatedwith BIS-11 second-
order attentional and nonplanning subscale scores. Level of
education was dichotomised into secondary school, referring to
participants who reported not progressing past secondary
school, and tertiary education, referring to participants who
reported entering into a tertiary level of education. Participants
who reported entering into a tertiary level of education were
considered as having a higher level of education.
General linear models (GLMs) were used to analyse the
relationship between variables identified as being significant in
the univariate models and the two BIS-II second-order sub-
scales. Variables proposed to be risk factors for the devel-
opment of impulse control disorders in PD were also included
in the GLMs, despite not displaying statistical significance in
the univariate models. Variables included in the GLMs were
gender, smoking history, dopamine agonist usage, LEDD,DBS
history, age at disease onset, disease duration, MDS-UPDRS
III scores, cognitive status, and participants’ level of education.
Nonsignificant variables were removed singularly in order of
least significance until the final models were determined.
3. Results
3.1. Cohort Information and Clinical Data. Mean demo-
graphic details and the results of clinical assessments are
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shown in Table 2. 'e predominantly male cohort ranged in
age and disease duration. At the time of the study, a total of
45 participants were medicated with dopamine agonists
(DAs), and 14 participants had undergone DBS therapy.
When examined according to MMSE score, 70 patients did
not display cognitive impairment, and 17 were classified as
being cognitively impaired. Overall, the cohort displayed
a mean total BIS-11 score of 62.5 (±8.9) and had no prior
history of impulsivity, based on information provided
during consultation with a clinical psychologist.
3.2. Univariate Association of Demographic and Clinical
Variables with Second-Order Attentional and Nonplanning
Impulsivity. Univariate regression models revealed selected
clinical and demographic variables associated with BIS-11
second-order attentional scores including gender (p � 0.048)
and MDS-UPDRS III rating (p � 0.005). 'e residuals from
these univariate models were normally distributed. 'e pa-
tients’ level of education was positively associated with BIS-11
second-order attentional scores; however, this association did
not reach statistical significance (p � 0.076). BIS-11 second-
order nonplanning scores were significantly associated with
gender (p � 0.001), MDS-UPDRS III rating (p � 0.001), and
disease duration (p � 0.003). While the residual values of the
univariate models for MDS-UPDRS III rating and disease
duration were normally distributed, those for gender were not.
3.3. Demographic and Clinical Predictors of Second-Order
Attentional Impulsivity in Multivariate Models. Multivariate
general linear models were fitted to identify demographic
and clinical determinants of BIS-11 second-order attentional
and nonplanning subscale scores. 'e residual values for these
multivariatemodels were normally distributed.Dopamine agonist
usage, LEDD, DBS surgery, age at onset, disease duration, and
cognitive status (cognitively impaired and not cognitively im-
paired) were found not to be significant predictors of BIS-11
second-order attentional or nonplanning subscale scores. In
contrast, being of male gender, no history of smoking, higher
level of education, and increased disease severity are pre-
dictive of elevated BIS-11 second-order attentional subscale
score when entered simultaneously in the model (Table 3).
Specifically, male participants were predicted to score
1.8 points higher than female participants (p � 0.011).
Table 2: Baseline clinical characteristics of the PD cohort (n � 87)
used in this study.




Age (years) 62.8 (9.2)
Age of onset (years) 53.3 (10.2)












Secondary school 58 (66.7%)
Tertiary education 29 (33.3%)
MDS-UPDRS III (motor) 18 (14.2)
Cognitive status
Cognitively impaired 22 (25.3%)
Not cognitively impaired 65 (74.7%)
BIS-11 scores
Attentional 2nd order 15.8 (3.7)
Nonplanning 2nd order 24.8 (4.9)
Total score 62.5 (8.9)
Table 1: Questions corresponding to BIS-11 second-order attentional and nonplanning domains.
BIS-11 2nd order subscale Corresponding questions
Attentional impulsivity
5. “I don’t pay attention”
6. “I have racing thoughts”’
9. “I concentrate easily”
11. “I squirm at plays or lectures”
20. “I am a steady thinker”
24. “I change hobbies”
26. “I often have extraneous thoughts when thinking”
28. “I am restless at the theatre or lectures”
Nonplanning impulsivity
1. “I plan tasks carefully”
7. “I plan trips well ahead of time”
8. “I am self controlled”
10. “I save regularly”
12. “I am a careful thinker”
13. “I plan for job security”
14. “I say things without thinking”
15. “I like to think about complex problems”
18. “I easily get bored when solving thought problems”
27. “I am more interested in the present than the future”
29. “I like puzzles”
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'e estimated marginal mean (EMM) BIS-11 attentional score
formale participants was 15.95 and 14.22 for female participants
(p � 0.019) (Figure 1). Patients with no smoking history were
predicted to score 2.2 points higher than those with a history of
smoking (p � 0.038), and patients who had pursued tertiary
studies were predicted to score 1.7 points higher than those who
had attained a secondary level of education (p � 0.023) on the
BIS-11 second-order attentional subscale. 'e EMM BIS-11
attentional score for those who undertook a secondary level
of educationwas 14.22 and 15.95 for those who pursued tertiary
studies (p � 0.023) (Figure 1). In addition to this, for every
additional MDS-UPDRS III point, BIS-11 second-order atten-
tional scores were predicted to rise by 0.07 points (p � 0.003).
For example, a male patient who did not report a history of
smoking was predicted to score 2.2 points higher than a female
patient who did report a history of smoking.
3.4. Demographic and Clinical Predictors of Second-Order
Nonplanning Impulsivity in Multivariate Models. Similarly,
multivariate general linear models indicated that being of
male gender, greater level of education, and increased dis-
ease severity were predictive of elevated BIS-11 second-order
nonplanning subscale scores (Table 4). Smoking history was
not found to be a significant determinant of nonplanning
subscale scores. Specifically, male participants were pre-
dicted to score three points higher than female participants
(p � 0.002). 'e EMM for BIS-11 nonplanning scores was
26.45 for male participants and 23.09 for female participants
(p � 0.001). 'ose who had pursued tertiary education
scored two points more than those who had attained
a secondary level of education (p � 0.047) on the BIS-11
second-order nonplanning subscale. 'e EMM for BIS-11
nonplanning scores was 23.79 for those who had attained
a secondary level of education and 25.76 for those who had
pursed tertiary education (p � 0.047) (Figure 1). In addition
to this, participants were predicted to score 0.1 points higher
for every additional MDS-UPDRS III score (p � 0.001) on
the BIS-11 second-order nonplanning subscale. For exam-
ple, a patient who obtained an MDS-UPDRS III rating of 50
was predicted to score 3.3 points higher on the BIS-11
second-order nonplanning domain than a patient who
obtained an MDS-UPDRS III rating of 20.
4. Discussion
Several risk factors for the onset of ICDs in PD subjects have
been identified, including gender [11], smoking history
[11, 13, 14], history of drug or alcohol abuse [9, 15], im-
pulsivity [9], and a novelty seeking personality [9, 15].
However, there are no established demographic or clinical
indicators for trait impulsivity in PD subjects. In light of the
close relationship between trait impulsivity and the devel-
opment of ICDs, and in conjunction with the absence of
treatments for impulsive behaviours, there is a growing need
to identify risk factors associated with impulsivity. Our
findings suggest that several demographic and clinical
variables may underlie impulsive behaviours in PD subjects.
Aligning with previous findings regarding PD-ICD
subjects, the current study suggests that being of male
gender is a significant risk factor for the development of trait
impulsivity [19, 20]. Male subjects displayed significant
associations between disease severity and the BIS-11 second-
order attentional and nonplanning subscales. Regression
analysis revealed that male subjects were predicted to score
higher, particularly in the BIS-11 second-order nonplanning
subscale, when compared with female subjects. A similar
gender-related pattern of impulsive behaviour has been
demonstrated in both PD-ICD subjects and the general
population. For instance, Kenangil et al. [20] reported that
among a cohort of 554 PD patients, 33 had a diagnosed ICD,
of which 81%weremen. In addition to this, male PD subjects
are more likely to develop pathological gambling and hy-
persexual behaviours than females, with a similar pattern
also evident in the general population [11].
'is predisposition to developing impulsive behaviours
in males may be related to men historically requiring greater
stimulation and therefore being more likely to engage in
sensation-seeking and impulsive behaviours than females
[21]. Studies exploring gender differences in impulsivity
have underlined that whilst females display heightened
punishment sensitivity and are thereforemore likely to avoid
danger or risk, males do not exhibit this trait which may
underlie the male propensity to partake in risky behaviours
and therefore display heightened impulsivity [22]. It is
important to note, however, that male PD subjects are less
likely to develop compulsive eating and shopping disorders
than female PD subjects, thus indicating that the type of
impulsive behaviour reported may be gender-specific [11].
To our knowledge, this is the first study to explore the
influence of level of education on the development of im-
pulsivity in PD. Given the association between lower edu-
cation status and accelerated cognitive decline in PD, the
current study investigated whether achieving lower level of
education (i.e., finishing secondary school and not pursuing
tertiary studies) may also be related to elevated trait im-
pulsivity [23]. However, the present study found that pur-
suing tertiary education and therefore pursuing education
after secondary school was a risk factor for elevated BIS-11
second-order attentional and nonplanning scores. Weintraub
et al. [11] identified a similar trend in a cohort of 3,090 PD
patients, with those diagnosed with an ICDmore likely to have
more formal education.We suggest that seeking and obtaining
Table 3: Final multivariate model parameter estimates: predictors
of BIS-11 second-order attention subscale scores.
Variable β coefficient Std. error p
(Intercept) 12.537 1.3095 0.000
Gender
Male 1.730 0.7401 0.019
Female 0∗ — —
Smoking history
Yes −2.207 1.0318 0.032
No 0∗ — —
Level of education
Secondary school 0∗ — —
Tertiary education 1.730 0.7581 0.023
MDS-UPDRS III 0.080 0.0253 0.002
∗Comparison category set to zero.
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further education may reect distortions in patients’ reward
processing, an important element of impulsivity, thereby
explaining this association between higher education status
and trait impulsivity. Neuroimaging studies have demon-
strated that PD patients, particularly those taking dopami-
nergic medication or with a clinically diagnosed ICD, may
exhibit blunted reward anticipation and experiencing [24, 25].
In turn, these patients often make riskier choices in order to
compensate for this diminished reward response [24, 25].
Although seeking out additional education is not necessarily
an inherently risky process, it may nonetheless be related to
patients’ reduced ability to process and experience reward,
possibly leading to dissatisfaction with their current education
status and in turn, stimulating patients to pursue further
education opportunities with diminished disinhibition.
Heightened disease severity was also a signicant de-
terminant of elevated BIS-11 second-order attentional and
nonplanning scores in the described cohort, suggesting a re-
lationship between more severe motor symptoms and future
trait impulsivity in PD. Indeed, previous studies have dis-
counted disease severity as a risk factor for the development of
ICDs in PD subjects. Instead, these studies have underlined an
association between motor complications as measured by the
MDS-UPDRS IV and the future onset of ICDs, associating
this link with elevated dopaminergic loads as a result of
dopaminergic medication usage [26, 27]. Despite this, a more
recent investigation of impulsivity as a multidimensional
rather than unitary construct (i.e., ICD±) has reported a link
between elevated MDS-UPDRS III scores and impulsivity
in a cohort of 30 PD patients [6]. In this study, linear re-
gression analysis veried that increased disease severity was
signicantly associated with impaired performance on a va-
riety of measures of impulsivity including the Frontal As-
sessment Battery, Stroop test, BIS-11, Stop-Signal Task (SST),
Go/No-Go task, and the Cambridge Gambling Task [6]. We
propose that the pathophysiological basis underlying this
association may be related to deteriorating motor symptoms
being reective of progressive brain atrophy and dopaminergic
depletion, which, in turn, has been shown to have implications
for performance on a variety of measures of impulsivity and
therefore may contribute to the development of impulsive
behaviours [6].
Table 4: Final multivariate model parameter estimates: predictors
of BIS-11 second-order nonplanning subscale scores.
Variable β coecient Std. error p
(Intercept) 22.154 1.0648 0.000
Gender
Male 3.366 0.9680 0.001
Female 0∗ — —
Level of education
Secondary school 0∗ — —
Tertiary education 1.971 0.9936 0.047
MDS-UPDRS III 0.106 0.0328 0.001











































































Figure 1: Estimated marginal mean (EMM) BIS-11 second-order subscale scores. EMM BIS-11 (a) attentional and (b) nonplanning scores
were signicantly higher in male subjects. EMM BIS-11 (c) attentional and (d) nonplanning scores were signicantly higher in those who
had pursued tertiary education when compared with those who had attained a secondary level of education.
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Contrary to previous reports, an absence of past smoking
was a significant risk factor for elevated BIS-11 second-order
nonplanning scores. Although a history of smoking has been
associated with the development of ICDs in PD subjects
[11, 13], our findings suggest otherwise with regard to
impulsivity, indicating an inverse relationship between past
smoking and trait impulsivity. However, given only 14
participants reported a history of smoking, this finding is
more likely attributed to the small sample size of smokers
included in the current cohort, as opposed to the presence of
a potential association between smoking history and
impulsivity.
A growing body of evidence exists to support the notion
that dopamine agonist [10] medication, administered to
alleviate the motor symptoms of PD in fact provokes ICDs in
PD subjects. DA usage has been associated with a 3.5-fold
increased risk of developing an ICD in PD patients [11].
Although the mechanism underlying this association re-
mains unclear, the ability of DAs to stimulate dopamine
receptors in the striatal limbic system, an area involved in
reward and motivation, may contribute to the development
of reward-driven and compulsive behaviours exhibited by
PD patients with ICDs [28]. Interestingly, dopaminergic
medication was not a significant determinant of trait im-
pulsivity in this PD cohort. 'ough dopaminergic medi-
cation use has been associated with ICDs in PD cohorts, the
prevalence of ICDs in only a fraction of PD patients treated
with DAs highlights the importance of underlying suscep-
tibility unrelated to dopaminergic medication use in the
development of impulsivity [11]. Further, a significant
proportion of PD patients have been diagnosed with an ICD
before the initiation of any antiparkinsonian treatment,
supporting the notion of underlying individual susceptibility
to ICDs [8]. 'erefore, the current finding further underlines
the importance of additional clinical and demographic factors
in the onset and development of impulsivity in PD.
5. Limitations
A number of limitations of the current study must be ac-
knowledged. Firstly, the self-report nature of the BIS-11 may
introduce a degree of bias in the gathered responses due to
patients often being less inclined to report impulsive ten-
dencies. Although the BIS-11 is frequently used as a measure
of impulsivity in PD studies, the BIS-11 was not originally
designed for use in a PD clinical setting, thereby somewhat
limiting the reliability of the BIS-11 second-order scales. As
the presence of depression or anxiety was not noted and
therefore patients with depression or anxiety were not ac-
tively excluded from the current study, the confounding
effect of these psychiatric disorders on impulsivity outcomes
was not controlled for. In addition to this, patients’ cognitive
status was determined using an MMSE cutoff score of 26,
which may not have accurately identified all patients
exhibiting signs of cognitive impairment. Further, available
data relating to the level of patient education indicated the
commencement of education after secondary school, but did
not necessarily provide information on study completion.
As such, this study cannot attribute tertiary education
attainment to a rise in BIS-11 domain scores, rather the mere
pursuit of tertiary education.
6. Conclusion
In conclusion, the current study identified several de-
mographic and clinical indicators of increased trait im-
pulsivity in PD including male gender, heightened disease
severity, an absence of past smoking, and higher level of
education. 'e identification of demographic and clinical
indicators of trait impulsivity in PD patients may serve as
a valuable clinical tool in facilitating the early recognition of
impulsivity and determining patients’ therapeutic regimen,
particularly regarding whether dopaminergic therapy may
provoke impulsive behaviours and likely ICDs in the future.
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